Key facts
- Notable investors include Yonghua Capital, Jifeng Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Edgene Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Edgene Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Edgene Biotech
Developer of gene editing breeding technology based in Wuhan, China. The company has a gene bank, a detection and analysis platform, a gene editing platform, a molecular biology platform, a high-throughput genetic transformation platform and a field test base, enabling clients to improve the efficiency of environmental control in all stages of genetically transformed crop cultivation.
- Sector
- Healthcare
- HQ
- Wuhan, China
- Founded
- 2019
- Employees
- 3
- Website
- edgene.com.cn/
- Ownership
- Privately Held (backing)
Edgene Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Edgene Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Edgene Biotech in its N-PORT filings yet. We sweep new filings monthly.